Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03248375 · ClinicalTrials.gov registry record · NA

Impact of Y90 Radiation Segmentectomy on HCC

A NA study of Hepatocellular Carcinoma, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
29
Enrollment target
1
Study location

NCT03248375 is a NA study of Hepatocellular Carcinoma that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 29 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03248375, a NA study of Hepatocellular Carcinoma, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

The aim of this pilot study is to assess the efficacy of radiation segmentectomy with Theraspheres in patients with unresectable hepatocellular carcinoma that would qualify for thermal ablation as per the BCLC guidelines, but are unable to receive thermal ablation due to unfavorable location of target lesions.

Conditions Studied

Interventions

  • RADIATION Radiation Segmentectomy

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2016-08-03
Est. Completion 2021-03-31
Phase NA

What the Registry Record Tells You About NCT03248375

The ClinicalTrials.gov registry entry for NCT03248375 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (89% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation Segmentectomy is the first listed.

NCT03248375 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03248375 about?

NCT03248375 is a clinical study titled "Impact of Y90 Radiation Segmentectomy on HCC". The aim of this pilot study is to assess the efficacy of radiation segmentectomy with Theraspheres in patients with unresectable hepatocellular carcinoma that would qualify for thermal ablation as per the BCLC guidelines, but are unable to receive thermal ablation due to unfavorable location of targ...

What is the current status of trial NCT03248375?

This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2016-08-03. Estimated completion is 2021-03-31.

What conditions does trial NCT03248375 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma.

What interventions are being tested in trial NCT03248375?

The interventions under investigation include: Radiation Segmentectomy (RADIATION).

Who is sponsoring clinical trial NCT03248375?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03248375 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.